JP2024515650A5 - - Google Patents
Info
- Publication number
- JP2024515650A5 JP2024515650A5 JP2023563210A JP2023563210A JP2024515650A5 JP 2024515650 A5 JP2024515650 A5 JP 2024515650A5 JP 2023563210 A JP2023563210 A JP 2023563210A JP 2023563210 A JP2023563210 A JP 2023563210A JP 2024515650 A5 JP2024515650 A5 JP 2024515650A5
- Authority
- JP
- Japan
- Prior art keywords
- lipid
- composition according
- mol
- lnp composition
- amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163176227P | 2021-04-17 | 2021-04-17 | |
| US63/176,227 | 2021-04-17 | ||
| US202163254948P | 2021-10-12 | 2021-10-12 | |
| US63/254,948 | 2021-10-12 | ||
| US202163274153P | 2021-11-01 | 2021-11-01 | |
| US63/274,153 | 2021-11-01 | ||
| US202263316568P | 2022-03-04 | 2022-03-04 | |
| US63/316,568 | 2022-03-04 | ||
| PCT/US2022/025076 WO2022221697A1 (en) | 2021-04-17 | 2022-04-15 | Lipid nanoparticle compositions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024515650A JP2024515650A (ja) | 2024-04-10 |
| JP2024515650A5 true JP2024515650A5 (https=) | 2025-04-21 |
Family
ID=81580499
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023563210A Pending JP2024515650A (ja) | 2021-04-17 | 2022-04-15 | 脂質ナノ粒子組成物 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20250090471A1 (https=) |
| EP (1) | EP4322920A1 (https=) |
| JP (1) | JP2024515650A (https=) |
| KR (1) | KR20240017792A (https=) |
| AU (1) | AU2022257050A1 (https=) |
| BR (1) | BR112023021477A2 (https=) |
| CA (1) | CA3216877A1 (https=) |
| CL (1) | CL2023003077A1 (https=) |
| CO (1) | CO2023015485A2 (https=) |
| CR (1) | CR20230536A (https=) |
| IL (1) | IL307738A (https=) |
| MX (1) | MX2023012235A (https=) |
| TW (1) | TW202308597A (https=) |
| WO (1) | WO2022221697A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024536406A (ja) * | 2021-10-08 | 2024-10-04 | スージョウ・アボジェン・バイオサイエンシズ・カンパニー・リミテッド | 脂質化合物及び脂質ナノ粒子組成物 |
| EP4638783A2 (en) | 2022-12-22 | 2025-10-29 | Intellia Therapeutics, Inc. | Methods for analyzing nucleic acid cargos of lipid nucleic acid assemblies |
| WO2024199282A1 (zh) * | 2023-03-28 | 2024-10-03 | 苏州艾博生物科技有限公司 | 脂质化合物和脂质纳米颗粒组合物 |
| AU2024279278A1 (en) | 2023-05-31 | 2025-12-18 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| WO2025049432A1 (en) * | 2023-08-28 | 2025-03-06 | Intellia Therapeutics, Inc. | Methods for editing hla-a in cells pre-screened for the absence of one or both alleles of hla-h*01 |
| WO2025049481A1 (en) * | 2023-08-28 | 2025-03-06 | Intellia Therapeutics, Inc. | Methods of editing an hla-a gene in vitro |
| WO2025064401A1 (en) | 2023-09-18 | 2025-03-27 | Intellia Therapeutics, Inc. | Nuclease resistant single stranded dna product for non-viral delivery to a cell and methods of production thereof |
| WO2025064396A1 (en) | 2023-09-18 | 2025-03-27 | Intellia Therapeutics, Inc. | Nuclease resistant double stranded dna product for non-viral delivery to a cell and methods of production thereof |
| WO2025128871A2 (en) | 2023-12-13 | 2025-06-19 | Renagade Therapeutics Management Inc. | Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents |
| WO2025137301A1 (en) * | 2023-12-20 | 2025-06-26 | Intellia Therapeutics, Inc. | Methods for rapid engineering of cells |
| WO2025240946A1 (en) | 2024-05-17 | 2025-11-20 | Intellia Therapeutics, Inc. | Lipid nanoparticles and lipid nanoparticle compositions |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030083272A1 (en) | 1997-09-19 | 2003-05-01 | Lahive & Cockfield, Llp | Sense mrna therapy |
| US20060051405A1 (en) | 2004-07-19 | 2006-03-09 | Protiva Biotherapeutics, Inc. | Compositions for the delivery of therapeutic agents and uses thereof |
| CA3009891C (en) | 2009-12-23 | 2020-09-15 | Novartis Ag | Lipids, lipid compositions, and methods of using them |
| EP2526199A4 (en) | 2010-01-22 | 2013-08-07 | Scripps Research Inst | PROCESS FOR PRODUCING ZINC FINGERUCLEASES WITH CHANGED EFFECT |
| CN103668470B (zh) | 2012-09-12 | 2015-07-29 | 上海斯丹赛生物技术有限公司 | 一种dna文库及构建转录激活子样效应因子核酸酶质粒的方法 |
| WO2014093655A2 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains |
| US20140310830A1 (en) | 2012-12-12 | 2014-10-16 | Feng Zhang | CRISPR-Cas Nickase Systems, Methods And Compositions For Sequence Manipulation in Eukaryotes |
| DK2931891T3 (da) | 2012-12-17 | 2019-08-19 | Harvard College | Rna-styret modificering af menneskelige genomer |
| CN107879960B (zh) | 2013-03-08 | 2021-06-22 | 诺华股份有限公司 | 用于传递活性成分的脂质和脂质组合物 |
| US20150165054A1 (en) | 2013-12-12 | 2015-06-18 | President And Fellows Of Harvard College | Methods for correcting caspase-9 point mutations |
| EP3083556B1 (en) | 2013-12-19 | 2019-12-25 | Novartis AG | Lipids and lipid compositions for the delivery of active agents |
| CN106794141B (zh) | 2014-07-16 | 2021-05-28 | 诺华股份有限公司 | 将核酸包封在脂质纳米粒主体中的方法 |
| JP6948313B6 (ja) | 2015-09-17 | 2022-01-14 | モデルナティエックス インコーポレイテッド | 治療剤の細胞内送達のための化合物および組成物 |
| WO2018073393A2 (en) | 2016-10-19 | 2018-04-26 | Cellectis | Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy |
| WO2019147805A2 (en) | 2018-01-26 | 2019-08-01 | The Board Of Trustees Of The Leland Stanford Junior University | Regulatory t cells targeted with chimeric antigen receptors |
| AU2020248337A1 (en) * | 2019-03-28 | 2021-11-04 | Intellia Therapeutics, Inc. | Compositions and methods for ttr gene editing and treating ATTR amyloidosis comprising a corticosteroid or use thereof |
| CN114127044A (zh) * | 2019-04-25 | 2022-03-01 | 英特利亚治疗股份有限公司 | 可电离的胺类脂质和脂质纳米颗粒 |
| CA3145913A1 (en) * | 2019-07-29 | 2021-02-04 | James Everett Dahlman | Nanomaterials containing constrained lipids and uses thereof |
-
2022
- 2022-04-15 EP EP22721589.4A patent/EP4322920A1/en active Pending
- 2022-04-15 KR KR1020237039429A patent/KR20240017792A/ko active Pending
- 2022-04-15 MX MX2023012235A patent/MX2023012235A/es unknown
- 2022-04-15 IL IL307738A patent/IL307738A/en unknown
- 2022-04-15 US US18/287,239 patent/US20250090471A1/en active Pending
- 2022-04-15 WO PCT/US2022/025076 patent/WO2022221697A1/en not_active Ceased
- 2022-04-15 CR CR20230536A patent/CR20230536A/es unknown
- 2022-04-15 CA CA3216877A patent/CA3216877A1/en active Pending
- 2022-04-15 JP JP2023563210A patent/JP2024515650A/ja active Pending
- 2022-04-15 AU AU2022257050A patent/AU2022257050A1/en active Pending
- 2022-04-15 TW TW111114501A patent/TW202308597A/zh unknown
- 2022-04-15 BR BR112023021477A patent/BR112023021477A2/pt not_active Application Discontinuation
-
2023
- 2023-10-16 CL CL2023003077A patent/CL2023003077A1/es unknown
- 2023-11-16 CO CONC2023/0015485A patent/CO2023015485A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024515650A5 (https=) | ||
| Liang et al. | Development and delivery systems of mRNA vaccines | |
| JP7600208B2 (ja) | 拘束された脂質を含むナノ材料およびその使用 | |
| Sasso et al. | The progress and promise of RNA medicine─ an arsenal of targeted treatments | |
| JP2022501412A5 (https=) | ||
| JP2022530043A5 (https=) | ||
| TWI271407B (en) | Methods and compositions for treating inflammatory response | |
| JP6280120B2 (ja) | 干渉ｒｎａの内在性メカニズムを調節することができる核酸配列を送達するための製剤 | |
| Qin et al. | Development of spherical nucleic acids for prostate cancer immunotherapy | |
| JPH04505752A (ja) | オリゴヌクレオチドを使用する癌治療用の方法及び組成物 | |
| US12084660B2 (en) | Therapeutic alteration of transplantable tissues through In Situ or Ex Vivo exposure to RNA interference molecules | |
| JP2002501511A (ja) | 脂質小胞への荷電した治療剤の高率封入 | |
| HUE025782T2 (en) | 5-Aza-cytosine-containing oligonucleotide analogs | |
| JP2013511964A (ja) | ｍｉＲＮＡ−１００を含む医薬組成物ならびに血管増殖および内皮炎症を調節するためのその使用 | |
| JP2022514956A (ja) | 細胞調節剤の送達のためのナノカプセル | |
| CN118215496A (zh) | 抗原和药物-脂质缀合物的免疫调节组合 | |
| Mao et al. | Optimized lipid nanoparticles enable effective CRISPR/Cas9-mediated gene editing in dendritic cells for enhanced immunotherapy | |
| Kim et al. | Strategy to Enhance Dendritic Cell‐Mediated DNA Vaccination in the Lung | |
| TW202120104A (zh) | 用於治療apoc3相關疾病及病症之方法 | |
| Li et al. | Cationic lipid-assisted nanoparticles for simultaneous delivery of CD47 siRNA and R848 to promote antitumor immune responses | |
| Abbasi Dezfouli et al. | Delivery Aspects for Implementing siRNA Therapeutics for Blood Diseases | |
| TW202425952A (zh) | 脂質奈米顆粒藥物綴合物 | |
| JP2023502182A5 (https=) | ||
| EP1771548B1 (fr) | Utilisation de dendrimeres pour stimuler la croissance cellulaire | |
| EP1409672A2 (fr) | Oligonucleotides antisens capables d'inhiber la formation des tubes capillaires |